Anthony Barsotti
Director/Board Member at Deerfield Management Co. LP (Private Equity)
Profile
Anthony Barsotti, Ph.D., is a Senior Director, Preclinical Pharmacology, Deerfield Discovery and Development, and joined the Firm in 2020.
Prior to Deerfield, Dr. Barsotti served as Director of Target Discovery Biology at Inzen Therapeutics.
Before Inzen, he served as a Principal Scientist (Molecular Signaling) at Kadmon Corporation.
He began his career as a Post-Doctoral Fellow at Pfizer in the Oncology Research Unit.
Dr. Barsotti holds a B.A.
in Biochemistry from University of Pennsylvania and a Ph.D.
in Biological Sciences from Columbia University.
Anthony Barsotti active positions
| Companies | Position | Start |
|---|---|---|
Deerfield Management Co. LP (Private Equity)
 Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Director/Board Member | 2019-12-31 |
Former positions of Anthony Barsotti
| Companies | Position | End |
|---|---|---|
Inzen Therapeutics, Inc.
 Inzen Therapeutics, Inc. BiotechnologyHealth Technology Part of Sonata Therapeutics, Inc., Inzen Therapeutics, Inc. is discovering and developing a novel class of medicines based on thanokine biology. The company is based in Cambridge, MA. Thanokine biology offers the potential for unprecedented approaches to prevent and treat cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. Inzen's thanokine product platform applies advances in mass spectrometry and machine learning, novel probes, unique assays, genetic and chemical biological technologies to characterize thanokine biology at scale and create drug candidates. Inzen Therapeutics harnesses signals of the cellular microenvironment to treat serious diseases. The company was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | Director/Board Member | - |
Training of Anthony Barsotti
| University of Pennsylvania | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Finance |
Inzen Therapeutics, Inc.
Inzen Therapeutics, Inc. BiotechnologyHealth Technology Part of Sonata Therapeutics, Inc., Inzen Therapeutics, Inc. is discovering and developing a novel class of medicines based on thanokine biology. The company is based in Cambridge, MA. Thanokine biology offers the potential for unprecedented approaches to prevent and treat cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. Inzen's thanokine product platform applies advances in mass spectrometry and machine learning, novel probes, unique assays, genetic and chemical biological technologies to characterize thanokine biology at scale and create drug candidates. Inzen Therapeutics harnesses signals of the cellular microenvironment to treat serious diseases. The company was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | Health Technology |
- Stock Market
- Insiders
- Anthony Barsotti
